Thymosin Beta-4
Thymosin beta-4 is a naturally occurring 43-amino-acid protein that regulates actin dynamics and cell migration and has demonstrated tissue-protective and reparative effects in cardiac, corneal, dermal, and hair-follicle research models, with human evidence still limited relative to the extensive animal literature.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
As the principal actin-monomer-sequestering protein in mammalian cells, thymosin beta-4 binds free G-actin and regulates the balance between monomeric and filamentous actin, directly influencing cell shape, motility, and the migration of endothelial cells, keratinocytes, and progenitor/stem cells into injured tissue. It activates integrin-linked kinase and related pro-survival, pro-migration signaling in cardiac and endothelial cells, promotes activation of quiescent hair follicle stem cells, and exerts anti-inflammatory effects associated with modulation of NF-κB-related signaling.
Typical results seen in research
In animal studies, thymosin beta-4 has improved cardiac cell survival and vascularization after experimental myocardial infarction, accelerated corneal epithelial healing and reduced inflammation after alkali injury, and promoted hair follicle stem cell activation and hair growth. Human evidence remains comparatively limited: a 2025 study reported outcomes with a recombinant thymosin beta-4 formulation in both mice and a small group of human patients with acute ST-elevation myocardial infarction, and small human/ocular studies exist, but broad human efficacy across the range of indications studied in animals has not been established.
How it’s commonly used
In research, thymosin beta-4 has been administered systemically by injection (subcutaneous, intravenous, or intraperitoneal in animal studies) and locally as eye drops in corneal wound-healing research; published protocols are generally confined to defined short-term injury or recovery windows rather than indefinite ongoing use.
- Cardiovascular Research · 2025 Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion
- Experimental Eye Research · 2002 Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury
- FASEB Journal · 2004 Thymosin beta4 increases hair growth by activation of hair follicle stem cells
- BMC Biology · 2024 Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.